Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $37
Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ: ZYME ) with a Overweight and raises the price target from $34 to $37.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.